{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:30:02Z","timestamp":1787319002285,"version":"build-2736575974"},"reference-count":35,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>Obinutuzumab (GA101) is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the Fc&amp;#947;RIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. Preclinical data demonstrated more efficient B-cell depletion in whole blood and superior antitumor activity in xenograft models of obinutuzumab as compared to the type I CD20 antibody rituximab. In previously untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities, obinutuzumab plus chlorambucil increased response rates and prolonged progression-free survival compared with rituximab plus chlorambucil. Obinutuzumab had an acceptable and manageable safety profile, with infusion-related reactions during the first infusion as the most common adverse event. Further phase I\/II clinical trials have also shown promising activity in other CD20-positive B-cell non-Hodgkin's lymphomas (NHL). Therefore, several clinical studies are planned or ongoing to investigate obinutuzumab with different combination partners in both untreated and relapsed\/refractory patients with different B-cell NHL entities, which in addition to CLL include diffuse large B-cell lymphoma and follicular lymphoma.<\/jats:p>","DOI":"10.1159\/000381524","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T08:16:46Z","timestamp":1434529006000},"page":"185-192","source":"Crossref","is-referenced-by-count":65,"title":["Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody"],"prefix":"10.1159","volume":"38","author":[{"given":"Valentin","family":"Goede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003805.pub2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.004"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.904513"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/9783527682423.ch62"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.781169"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400288"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301249"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504043"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305847"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263533"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330357"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.001"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37884"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.948414"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0385"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.856008"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586610"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9718"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-331702"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000107"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/381524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/381524","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/381524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:55:16Z","timestamp":1745416516000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000381524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000381524","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}